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A microdeletion at Xq22.2 implicates a
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intellectual disability, behavioral problems
and craniofacial anomalies
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Abstract
Background: Among the 21 annotated genes at Xq22.2, PLP1 is the only known gene involved in Xq22.2 microdeletion
and microduplication syndromes with intellectual disability. Using an atypical microdeletion, which does not encompass
PLP1, we implicate a novel gene GLRA4 involved in intellectual disability, behavioral problems and craniofacial anomalies.
Case presentation: We report a female patient (DGDP084) with a de novo Xq22.2 microdeletion of at least 110 kb
presenting with intellectual disability, motor delay, behavioral problems and craniofacial anomalies. While her phenotypic
features such as cognitive impairment and motor delay show overlap with Pelizaeus-Merzbacher disease (PMD) caused
by PLP1 mutations at Xq22.2, this gene is not included in our patient’s microdeletion and is not dysregulated by a
position effect. Because the microdeletion encompasses only three genes, GLRA4, MORF4L2 and TCEAL1, we investigated
their expression levels in various tissues by RT-qPCR and found that all three genes were highly expressed in whole
human brain, fetal brain, cerebellum and hippocampus. When we examined the transcript levels of GLRA4, MORF4L2 as
well as TCEAL1 in DGDP084′s family, however, only GLRA4 transcripts were reduced in the female patient compared to her
healthy mother. This suggests that GLRA4 is the plausible candidate gene for cognitive impairment, behavioral problems
and craniofacial anomalies observed in DGDP084. Importantly, glycine receptors mediate inhibitory synaptic transmission
in the brain stem as well as the spinal cord, and are known to be involved in syndromic intellectual disability.
Conclusion: We hypothesize that GLRA4 is involved in intellectual disability, behavioral problems and craniofacial
anomalies as the second gene identified for X-linked syndromic intellectual disability at Xq22.2. Additional point
mutations or intragenic deletions of GLRA4 as well as functional studies are needed to further validate our hypothesis.
Keywords: GLRA4, Xq22.2, Pseudogene, Intellectual disability, Behavioral problems, Craniofacial anomalies, Microdeletion
Background
Intellectual disability (ID) is a genetically heterogeneous
condition with 2 % of the population estimated to be im-
pacted by this disorder [1, 2]. Such impairment of cogni-
tive functions places a high burden on families as well as
society making ID an important problem in medicine
[3]. Notably, X-linked intellectual disability (XLID) is ap-
proximately 4 times more prevalent than autosomal
forms [4]. Of the ~1,098 genes residing on the X
chromosome [5], a large number play a role in neuro-
logical functions [4, 6], and some of these genes are
highly expressed in the brain [7]. More than 100 ID
genes residing on the X-chromosome have been identi-
fied, and it is thought that more XLID genes are yet to
be discovered, particularly in X-linked families where the
genes map to new loci [2, 8–10].
Being approximately 1 Mb in size, chromosomal
segment Xq22.2 contains at least 21 annotated genes
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including TCEAL1 (MIM 300237), MORF4L2 (MIM
300409), PLP1 (MIM 300401) and an apparent pseudo-
gene (GLRA4) [11]. Among these genes, PLP1 mutations
have been previously shown to be associated with the
neurological disorder Pelizaeus-Merzbacher disease (MIM
312080) characterized by intellectual disability, nystagmus,
ataxia, spasticity, and microcephaly. Brain MRI revealed
macrogyria, dysmyelination, and increased paramagnetic
signal which is indicative of iron deposition [12, 13]. Fur-
thermore, PLP1 is also involved in Xq22.2 microdeletion
and microduplication syndromes [8].
The apparent human pseudogene glycine receptor α4-
subunit (GLRA4) lacks the 4th transmembrane domain
(TM4) located at the C-terminal end of the protein [11,
14, 15]. Glycine receptors (GLRs) are important in medi-
ating inhibitory neurotransmission in the brain [14, 16,
17]. However, the role played by GLRA4 in humans is
unclear because the absence of the TM4 domain is ex-
pected to be damaging to GLRA4 protein function [13].
Pseudogenes have been long considered as silent relics res-
iding in the genome as neutral sequences with no biological
roles [18, 19]. However, over the past decade, evidence is
mounting that pseudogenes have biological functions and
may play a role in health and disease [19–22]. For instance,
post-transcriptional silencing of HMGA1 (MIM 600701) by
its pseudogene (HMGA1-p) leads to insulin resistance and
type 2 diabetes [22]. Similarly, pseudogene PTENP1 has
been shown to exert a growth-suppressive role by regulat-
ing the transcript levels of the tumor suppressor gene
PTEN (MIM 601728) [21].
Here, we report an 11-year-old female patient present-
ing with intellectual disability, behavioral problems and
craniofacial anomalies. We performed microarray and
identified an apparent ~105 Kb microdeletion at Xq22.2.
The genomic deletion encompasses the genes TCEAL1
(MIM 300237),MORF4L2 (MIM 300409) and an apparent
pseudogene GLRA4. We performed qPCR to refine the
locations of the proximal as well as the distal deletion
breakpoints. The myelin proteolipid protein-coding gene
(PLP1) resides ~ 46 kb distal to the microdeletion. We
examined the transcript levels of GLRA4, TCEAL1,
MORF4L2 as well as PLP1 (MIM 300401) in the patient
and family members. The protein levels of PLP1 were also
examined by Western blot to determine whether PLP1 is
dysregulated by a position effect. We assayed the level of
transcripts of GLRA4, MORF4L2, and TCEAL1 in the
brain and other tissues. We hypothesize that GLRA4 is a
novel candidate gene for XLID and is likely involved in
the clinical features observed in our patient including cog-
nitive impairment, behavioral problems and speech delay.
Case presentation
The proband (DGDP084) is an 11-year-old girl born
after normal pregnancy and delivery. At birth, she
weighed 2.83 kg. She passed her neonatal hearing screen
test and did not require admission to the special care
unit. At around 8 weeks, the infant started manifesting
nystagmus. An MRI turned out to be normal. At 8
months, her parents started to have concerns about her
motor skills. She was not yet sitting or weight bearing.
She continued to display jerky eye movement and
showed some reluctance to elevate her eyes. Upon
examination at 9 months, development of her gross
motor skills was found to be delayed. At 15 months, her
gross motor skills were determined to be at the 9-
month-level. Her parents also noted that she was slow
to develop movement patterns, particularly involving ro-
tation. At that time, the infant was described as a happy,
smiling little girl.
When examined at 20 months, she was still showing
developmental delay. She was not yet crawling, and used
a lot of jargon with no clear words. She was able to roll
and enjoyed clapping and waving goodbye. At 2 years
and 1 month she had a brief generalized tonic clonic
seizure associated with fever. As a 2 year and 3-month
old girl, she was able to recognize her name and under-
stand the names of familiar adults. She was crawling effi-
ciently and enjoyed turning pages of her books. She was
able to bring a spoon to her mouth, but required her
parents’ assistance for loading. A thyroid function test
performed at 2 years and 8 months did not detect any
abnormalities. Her development at that time was quite
significantly delayed in many areas and she was func-
tioning at around the 12-month level. She walked with a
wide spaced ataxic gait and displayed some stereotypical
hand movements. The girl also had episodes where she
would stare and look blankly for approximately 10 s. She
displayed some of the physical and behavioral features of
Angelman syndrome. She has had extensive testing of
genetic changes normally seen in children with Angel-
man syndrome. This has excluded a maternally inherited
deletion, uniparental disomy, CNV analysis, abnormal
methylation at 15q11-q13, or a mutation in UBE3A gene
as causative. As some children with MECP2 deletions
have an Angelman-like phenotype, gene testing of MECP2
(MIM 300005) was also done, which was also negative.
Mowat-Wilson syndrome (MIM 235730), clinically similar
to Angelman syndrome, is caused by mutations of SIP1
(aka ZEB2, MIM 605802). Mutation screening of this
gene was negative. Although Angelman syndrome patients
show specific EEG patterns, an EEG showed no specific or
paroxysmal abnormality in DGDP084. This suggests that
she was not suffering from Angelman syndrome.
At 3 years and 4 months, the patient had a head cir-
cumference at 49.5 cm (50th centile). She had deep blue,
lightly pigmented irides and displayed frontal bossing as
well as a flat occiput. The patient also had a prominent
chin (Fig. 1a) and displayed fifth finger clinodactyly
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(Fig. 1e and f). When she was examined at 4 years-1-
month, her parents revealed that their daughter’s sleep
patterns were disturbed. She would wake up in the mid-
dle of the night and start banging on her window. At 4
years-7-months, she displayed global developmental
delay, hypermetropic astigmatism, and minor jerky eye
movement. Her height was at the 25th centile and
weight on the 75th centile. At that time, she was also en-
rolled in special schooling. She had several episodes of
significant abdominal pain associated with constipation
and was being treated with Movicol.
As a 5-year-old girl, the patient displayed significant
learning difficulties. She was also experiencing intermittent
episodes of distress during which she was making straining
noises. These episodes occurred approximately every
month or two, lasting up to one week. During those epi-
sodes, she often sat in an unusual position with her legs
folded underneath, her head held back and in a dream-like
state. She was also diagnosed with glycosuria. At that time,
the patient had a head circumference of 55.5 cm (between
the 9th and 25th centile), weighed 19.4 kg (50th centile),
and her height was at 107.4 cm (25th centile). Her sleep
patterns were still variable despite being treated with Mela-
tonin. She continued to have an ataxic wide-based gait and
displayed stereotypic arm movements with hand flapping.
She also had a tendency to walk in a side-to-side stepping
Fig. 1 Facial and hand pictures of patient DGDP084. Facial picture showing a broad face with prominent chin at (a) 9 years and 2 months (c) 12
years and 2 months. Lateral facial view of the patient showing low-set ears at (b) 9 years and 2 months (d) 12 years and 2 months. Hands and finger
shape (e and f) showing fifth finger clinodactyly as well as mild tapering of fingers at 9 years and 2 months
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instead of forward stepping. Microarray analysis revealed a
deletion at Xq22.2.
When examined as a 6-year-old girl, she weighed 18.7 kg
(9th-25th centile), and her height was 110.1 cm (9th-25th
centile). She displayed poor coordination, and her speech
had not yet developed. The girl was diagnosed with Type 1
diabetes, and a heart murmur was also detected. She con-
tinued to have problems with constipation and was taking
Chloral hydrate. Her parents mentioned that her problem-
atic sleep patterns were becoming a concern as the banging
noises were disturbing neighbors. The repeated banging
also left marks on her wrist, and she was also eating non-
food items. She was dependent on her parents for all her
personal care and was also enrolled in occupational ther-
apy. While still a 6-year old girl, she had chicken pox, which
was mild in nature. She continued to have unsettled nights
as a 7-year-old girl and at that time the abdominal discom-
fort was thought to be presumably responsible. A summary
of DGDP084 clinical features is provided in Table 1.
Family history is unremarkable except for the father,
paternal grandmother and a maternal cousin. The pa-
tient’s father has Type I diabetes, while the maternal
cousin displays cerebral palsy. The paternal grandmother
had a number of stillborn babies.
Methods
Lymphoblastoid cell lines were made from blood sam-
ples obtained from patient DGDP084 and her parents
using a density gradient centrifugation method following
Nishimoto et al. [23]. Genomic DNA was isolated from
blood samples using a standard phenol-chloroform
protocol with minor modifications. The extracted gen-
omic DNA from the patient’s blood was examined on a
comparative genomic hybridization array (aCGH) to
detect pathogenic copy number variations (CNVs) as de-
scribed [24]. The X chromosome inactivation (XCI) pat-
tern using genomic DNA from patient DGDP084 was
determined by PCR analysis of a polymorphic CAG re-
peat in the first exon of the androgen receptor (AR)
gene. Methylation of sites close to this short tandem
repeat has been demonstrated to correlate with X
chromosome inactivation [25]. In this assay, amplification
of the AR gene both before and after digestion with the
methylation-sensitive HpaII restriction enzyme was used
to determine the methylation status of the maternal and
paternal X chromosome. XCI degree threshold patterns
are classified as random (XCI < 80 %), moderately skewed
(80 % ≤ XCI ≤ 90 %), and highly skewed (>90 %) [26].
Primers targeting the putative proximal and distal dele-
tion breakpoints at Xq22.2 were designed for qPCR. We
also made primers against exonic sequences of GLRA4,
TCEAL1, MORF4L2, and PLP1 for qPCR as well as RT-
qPCR (Additional file 1: Table S1). Total RNA was ex-
tracted from cell lines using the RNeasy Plus Mini kit
(Qiagen) following the manufacturer’s instructions. RT-
qPCR was performed using total RNA (Clontech) from
whole human brain, fetal brain, cerebellum, cerebral cor-
tex, hippocampus, kidney, liver, lung, heart and skeletal
muscle. cDNA was synthesized from 1 μg of total RNA
using the RevertAid First cDNA Synthesis Kit (Thermo
Scientific). Real-Time PCR was carried out using 2 μl
cDNA, 2.5 μM primer and 10 μl FastStart DNA Green
Master (Roche) in a 20 μl reaction volume. Samples were
run in triplicates and standard errors were calculated from
2–3 independent experiments. The ΔΔct method was
used to determine copy number of the loci of interest as
well as relative transcript levels of genes of interests. The
beta-2-microglobulin (MIM 109700) gene was used for
Table 1 Clinical features of DGDP084 compared with other patients having small-sized microdeletions within the Xq22.2 interval
Clinical features DGDP084 Yamamoto Torisu Inoue 2002 Inoue 2002 Inoue 2002 Matsufuji 2013
2014 Pt5 2012 Pt 1 Pt 2 Pt 3 Pt II-1
F F M M M M M
Intellectual disability + + + + + + +
Speech delay + + + NS + + +
Motor delay + + + + + + +
Impaired social skills + + - NS + NS +
Sleep disturbance + + NS NS NS NS NS
Behavioral problems + + NS NS NS NS NS
Seizures + - NS NS - NS -
Craniofacial anomalies + + + NS NS NS NS
Tapering fingers & clinodactyly + - NS NS NS NS NS
Brain MRI – delayed myelination - + + + + NS +
Cardiac anomalies + - NS NS NS NS NS
Gastrointestinal problems + - NS NS NS + +
NS not stated, Pt patient, F represents female while M denotes male
Labonne et al. BMC Neurology  (2016) 16:132 Page 4 of 12
data normalization. Numerical means and standard devia-
tions for qPCR and RT-qPCR are provided in Additional
file 1: Table S2 and S3, respectively. Protein was isolated
from cell lines derived from patient DGDP084 and family
members. Anti-PLP1 antibody (Abcam) targeting amino
acids109-128 was used to detect PLP1 protein expression
levels. A dilution of 1:1000 was used for the primary anti-
body, while the secondary anti-rabbit antibody (Thermo
Scientific) was diluted 1:1000. Detection was carried out
using the Amersham™ ECL™ Western Blotting Analysis
System (GE Healthcare).
Results
Microarray analysis reveals a microdeletion in patient
DGDP084 at Xq22.2
A 105 kb minimal microdeletion at Xq22.2 (chrX:
102,882,657-102,987,229, hg 19) was detected by micro-
array analysis with a putative maximal deletion determined
to be ~ 145 kb (chrX:102,857,905-103,002,957, hg 19). The
deleted genomic region contains only three genes namely,
MORF4L2, GLRA4, and TCEAL1 (Fig. 2 and Table 2).
Microdeletion occurred as a de novo event
qPCR assays using genomic DNA and primers targeting
GLRA4 confirmed the Xq22.2 microdeletion in female
DGDP084 and also revealed that the chromosomal re-
arrangement occurred as a de novo event. As expected,
the patient’s healthy mother possesses two copies of
GLRA4, while the healthy father has only one copy
(Fig. 3a). According to qPCR analysis the size of the
microdeletion is at least 110 kb and does not extend into
the proximal genes, TCEAL3 and PLP1. The centromeric
deletion breakpoint resides in the intergenic region 1 be-
tween TCEAL1 and TCEAL3, while the telomeric break-
point was found to reside in the intergenic region 2
between GLRA4 and PLP1 (Figs. 2 and 3b).
Transcript levels of GLRA4 are reduced in patient
DGDP084
Analysis of GLRA4 transcript levels by RT-qPCR revealed
low GLRA4 expression in DGDP084 girl similar to her
healthy father, but much lower than her mother (Fig. 4a).
The transcript levels of MORF4L2 in DGDP084 were
statistically not different to her parents (Fig. 4b). TCEAL1
Fig. 2 Comparative deletion mapping at Xq22.2 showing the size of the microdeletion in DGDP084 relative to six other patients. GLRA4 is
completely deleted in three patients. All six genomic deletions involve PLP1, except the microdeletion in DGDP084. The distal breakpoints of the
three microdeletions reported by Inoue et al. [29] extend well beyond the RAB9B gene. However, the distal breakpoint in the patient described in
Torisu et al. [28] is located immediately distal to RAB9B
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transcript level was consistent across all family members
(Fig. 4c). The levels of PLP1 transcripts in DGDP084 were
statistically not different to her healthy mother (Fig. 4d).
Random X-chromosome inactivation in DGDP084
X-inactivation studies revealed an inactivation ratio of
77:23. Since inactivation ratios of less than 80:20 are
considered random patterns, this suggests a random in-
activation of chromosome X in this microdeletion female.
The X-chromosome with the Xq22.2 microdeletion in
DGDP084 is not preferentially inactivated.
GLRA4, MORF4L2 and TCEAL1 are highly expressed in the
brain
Transcripts of GLRA4 were ~25-fold higher in whole
human brain relative to lymphocytes. Little or no
GLRA4 transcripts were detected in the heart, kidney,
Table 2 Genes deleted in DGDP084
Gene Gene
symbol
OMIM# Remarks
Glycine receptor,
alpha 4 subunit
GLRA4 - Glycine receptors mediate
neurotransmission in the
spinal cord and brain stem.
Human GLRA4 is considered
as a pseudogene and has a
stop codon before the
predicted transmembrane
domain (exon 9) [11, 36].
Mortality factor
4 like 2
MORF4L2 300409 May be implicated in cellular
senescence like 2 [52]. The
mouse homolog (MgrX) is not
essential for growth and
development [37]
Transcription
Elongation
Factor A-Like 1
TCEAL1 300237 Nuclear phosphoprotein having
48 % Elongation homology to
transcription factor SII factor
A-like-1 [53].
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Fig. 3 Refining deletion breakpoints in DGDP084. a qPCR assays confirmed the Xq22.2 microdeletion in DGDP084. GLRA4 copy number in
DGDP084 was compared to her mother as a gender control. The patient’s mother was normal possessing two copies of GLRA4, while the father
and the affected female DGDP084 have only one GLRA4 allele on the chromosome X. b The copy number of genes and loci in DGDP084 at
Xq22.2 were compared to her mother. The TCEAL1 gene was found to be completely deleted with the proximal deletion breakpoint lying
between TCEAL1 and TCEAL3. The distal deletion breakpoint was located in the non-genic region between GLRA4 and PLP1. Asterisks denote differences
that are statistically significant
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liver, lung, and skeletal muscle (Fig. 5a). The level of
MORF4L2 transcripts was ~24-fold higher in the brain,
and 10-fold higher in skeletal muscle relative to
lymphocytes (Fig. 5b). Very low levels of MORF4L2
transcripts were detected in other tissues assayed.
Transcript levels of TCEAL1 were extremely high in
the brain (~50-fold) compared to lymphocytes (Fig. 5c).
High levels of TCEAL1 transcripts (20-fold) were also
detected in skeletal muscle relative to lymphocytes.
Kidney, liver and lung expressed very low levels of
TCEAL1 transcripts.
Transcripts of GLRA4, MORF4L2 and TCEAL1 were
abundantly expressed in fetal brain, cerebellum, cerebral
cortex and hippocampus (Fig. 5d-f ). The highest tran-
script levels were detected in fetal brain where an ~60-
fold, ~30-fold, ~90-fold higher level of transcripts were
detected for GLRA4, MORF4L2 and TCEAL1, respect-
ively relative to lymphocytes.
Western blot shows that PLP1 is not dysregulated by
position effect
By densitometry, the PLP1 protein was found to be
expressed at the same levels in DGDP084, her par-
ents and the two controls as normalized to GAPDH
(Fig. 6). No gender difference in PLP1 protein ex-
pression was observed across the individuals assayed.
We did not detect GLRA4 protein in lymphocytes
but low levels were expressed in fibroblasts (data not
shown).
Comparative deletion mapping at Xq22.2
We performed comparative deletion mapping with
DGDP084 and six additional informative microdeletions
at Xq22.2 (Fig. 2). Patient II-1 of Matsufuji et al. [27] has
a 33-kb microdeletion spanning PLP1 only. The CNV in
patient 5 of Yamamoto et al. [8] encompasses GLRA4
and PLP1only, while the microdeletion in the patient of
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Fig. 4 Assaying transcript levels of GLRA4, MORF4L2, TCEAL1, and PLP1 by RT-qPCR. Transcript levels of the aforementioned genes in DGDP084
were compared to the patient’s mother as a gender control. a GLRA4 transcripts were reduced in the female DGDP084 to the level of
her healthy father compared to her healthy mother. b MORF4L2 and c TCEAL1 transcripts levels were similar in all family members. d The level of
transcripts of PLP1 was slightly increased in DGDP084, while a moderate reduction was noted in the patient’s father. However, both changes observed
were statistically insignificant. Please see western blot of PLP1. Asterisks denote differences that are statistically significant
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Torisu et al. [28] includes PLP1 and RAB9B only. Patient
2 of Inoue et al. [29] has a microdeletion involving at
least MORF4L2, GLRA4, PLP1, RAB1 whereas his
patients 1 and 3 of Inoue et al., [29] have CNVs encom-
passing at least PLP1 and RAB9B. The deletion break-
points of the three patients reported in Inoue et al. [29]
have not been clearly defined. It is possible that GLRA4
is dysregulated in patients 1 and 3 due to a position ef-
fect, in case their centromeric breakpoints do not affect
GLRA4. Our patient DGDP084 without the deletion of
PLP1 displays clinical features including intellectual dis-
ability, speech delay, and craniofacial anomalies which
are also present in the patient of Torisu as a result of
PLP1 deletion (Table 1). Interestingly, patients displayed
a wider range of clinical features when GLRA4 is in-
cluded in the Xq22.2 microdeletion. In the case of
DGDP084, the phenotype was more severe compared to
other patients.
The fourth transmembrane domain (TM4) is conserved
among several species except human
Amino acid residues of GLRA4 are evolutionarily con-
served throughout the seven mammalian species. Only
human GLRA4 (NP_001019623.2) shows an absence of
40 amino acids at the C-terminal region, part of which
codes for the fourth transmembrane domain TM4
(Fig. 7) [11]. The amino acid sequence of the TM4 do-
main is highly conserved among other species.
Discussion
The Xq22.2 region harbors PLP1 causative for Pelizaeus-
Merzbacher disease characterized by cognitive impairment,
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Fig. 5 Transcript levels of GLRA4, MORF4L2 and TCEAL1 in the brain and other tissues. All three X-linked genes are highly expressed in the brain
relative to lymphocytes. Low levels of transcripts were detected in the heart, kidney, liver and lung. Fetal brain and cerebellum showed the highest
expression of GLRA4, MORF4L2 and TCEAL1. High level of transcripts was also detected in the hippocampus compared to lymphocytes
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severe spasticity, hypotonia, nystagmus and ataxia [12].
Most of the CNVs in this interval include PLP1 and
neighboring genes, suggesting the occurrence of microdele-
tion and microduplication syndromes at Xq22.2 with
phenotypic features including intellectual disability (ID),
behavioral abnormalities, and hypotonia [8]. The patient
DGDP084 investigated in the present study displays
intellectual disability, behavioral problems, and craniofacial
anomalies. She has a de novo Xq22.2 microdeletion of at
least 110 Kb encompassing only three annotated genes
namely,MORF4L2 and TCEAL1 as well as an apparent hu-
man pseudogene GLRA4 [11, 14, 15]. Both microarray and
qPCR (Fig. 3) show that PLP1 located immediately distal to
GLRA4 is not deleted (Fig. 2). Moreover, DGDP084 did not
display anomalies in myelination, and the brain scan (MRI)
performed was normal, making it highly unlikely that PLP1
is the underlying cause of the clinical features. This is sub-
stantiated by Western blot showing similar levels of PLP1
expression in DGDP084 and her parents (Fig. 6), suggesting
this gene is not dysregulated by a position effect. The cyto-
genetic band of Xq22.2 with a large interval of 1 Mb con-
taining at least 21 annotated genes suggests the presence of
one or more XLID genes in this region. So far, PLP1 is the
only gene known to be involved in XLID, and importantly,
this is the first case of microdeletion with syndromic intel-
lectual disability at Xq22.2 without involvement of PLP1.
Conspicuously, the transcript levels of GLRA4 were signifi-
cantly reduced in DGDP084 compared to her healthy
mother and this is consistent with the random X-
inactivation result suggesting chromosome X with the
Xq22.2 microdeletion is not preferentially inactivated. The
higher dosage of GLRA4 in the healthy mother compared
to her healthy husband suggests that females express higher
levels of GLRA4 compared to males by either escaping X-
inactivation or incomplete silencing of the inactive X
chromosome occurred in this family. Notably, MORF4L2
and TCEAL1 transcripts were expressed at similar levels in
the patient and her parents. The transcript levels of GLRA4,
MORF4L2 and TCEAL1 were significantly higher in the
whole human brain and fetal brain compared to other tis-
sues such as heart, liver and kidney (Fig. 5a-c). High level of
transcripts of all three genes were detected in various areas
of the brain including the cerebellum and hippocampus
(Fig. 5d-f), regions of the brain known to be associated with
learning and memory [30]. The reduction of GLRA4 tran-
script levels in DGDP084 in the family coupled with its ex-
pression pattern in the brain suggest that GLRA4 is the
plausible candidate gene for the clinical features observed
in DGDP084 including intellectual disability, behavioral ab-
normalities, and craniofacial anomalies. Interestingly, the
phenotype observed as a result of the microdeletion in
DGDP084 shows overlap with the clinical features pro-
duced as a result of PLP1 disruption including cognitive
impairment and motor delay [8, 31] suggesting that both
DGDP084 Mother Father
PLP1
0
0.5
1
DGDP084 Mother Father White female
control
White male
control
D
en
si
ty
Individual
White female
control
White male
control
GAPDH
Fig. 6 Western blot showing PLP1 expression levels in DGDP084 and
her family members. The protein level of PLP1 in the patient was similar
to her parents as well as the white female and male controls. GAPDH
protein levels were used as a reference for densitometry analysis
Fig. 7 GLRA4 C-terminal end amino acid alignment across seven species including mouse, human, gorilla, monkey, camel, sheep and cow. The
last 90 amino acids are displayed along with the location of the TM4 domain. Human GLRA4 is the only species missing the conserved TM4 domain
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genes, physically located in close proximity, may participate
in similar molecular function.
Comparable levels of TCEAL1 and MORF4L2 tran-
scripts were detected in DGDP084 and her parents
(Fig. 4b and c). This means that even if their high level
of expression in the human brain and skeletal muscle
(Fig. 5b and c) suggests a role in neurological and motor
function, these genes may be excluded as contributing to
cognitive impairment, behavioral abnormalities and cra-
niofacial anomalies. Additional point mutations or intra-
genic deletions of GLRA4 and functional studies are
required to support our hypothesis. It is interesting to
note that TCEAL1 has been shown to interact with
PTPN11 [32], the causative gene for Noonan syndrome
characterized by short stature, craniofacial anomalies,
pectus deformities, webbed neck and sometimes ID
[33, 34]. Moreover, Mrgx, the mouse orthologue of
MORF4L2 (aka MRGX, MIM 300409) has been shown
to interact with HNRNPK [35], a gene known to be asso-
ciated cognitive impairment [36]. However, knockout of
Mgrx does not affect mouse development as the mice re-
main healthy and fertile [37].
Glycine receptor chloride channels (GLR) are penta-
meric proteins belonging to the Cys-loop family of ligand-
gated ion channel receptors [14]. A total of five glycine
receptor chloride channel subunit genes exist in humans,
and these channels are usually composed of homo-
or hetero-pentamers arranged around a central ion-
conducting pore [38]. Functional homomeric α-GLRs
have been shown to be assembled in the human embry-
onic kidney HEK-293 cell line [39], and their activation
mechanisms have been studied in rat [40]. Most GLRs are
assembled from four α-subunits (GLRA1, GLRA2, GLRA3
and GLRA4) and one β-subunit (GLRB) [15, 41, 42]. Each
subunit has an extracellular domain containing the neuro-
transmitter binding site, and a transmembrane domain
comprising four transmembrane α-helices (TM1-TM4)
connected by flexible loops [43]. The α subunits show a
high degree of amino acid identity [44] indicating that
they evolved by gene duplication [16, 45]. Being a trans-
membrane protein, GLRs selectively allow passage of Cl-
ions when glycine binds at specific sites on the receptor
surface [41, 46]. GLRs are important in mediating inhibi-
tory neurotransmission in a number of regions of the
brain including mammalian brainstem and spinal cord
where they are widely expressed [14, 16, 17]. Through
electron microscopy, it has been shown that in rats GLRs
are tightly packed around presynaptic terminals at central
synapses [41, 46]. The functional importance of GLRs and
the observed patterns of expression of GLRA4 in the brain
are consistent with a role in cognitive deficits and behav-
ioral abnormalities observed in patient DGDP084.
Previously, it has been shown that mutations in the α1
subunit of glycine receptor (GLRA1) are responsible for
the neurological disorder hyperekplexia (MIM 149400)
characterized by muscle rigidity originating from the
CNS as well as an exaggerated startle response [47].
Sudden muscle contractions are often observed in in-
fancy and can sometimes lead to death possibly due to
apnea or aspiration [48, 49]. Interestingly, a male patient
possessing both missense and splice site mutations in
GLRB, a β-subunit of the pentameric GLRs, has been re-
ported to display hyperekplexia [50]. This shows that
subtle alterations in the structure of GLRs can affect
functioning of this ligand-gated ion channel in the brain.
Our patient DGDP084 does not have hyperekplexia and
it is possible that the cognitive impairment and unusual
behaviors displayed by DGDP084 such as banging on
windows and furniture may be due to reduced GLRA4
expression in the brain disrupting the composition of
heteromeric GLRs. It is interesting to note that patients
with hyperekplexia display delay in speech acquisition
and ID which usually normalize in infancy [43, 51].
In humans, the role of GLRA4 in the functioning of
GLRs is unclear because of the stop codon in exon 9 up-
stream of the predicted TM4 domain common in the
three other human α subunits [11]. The sequence of each
of the three GLR genes (α1- α3; GLRA1, GLRA2, GLRA3)
encodes four TM domains which act as important barriers
between the ion permeation pathway and the apolar areas
of the lipid bilayer [41]. The absence of the TM4 domain
in GLRA4 is thought to produce an inactive protein [11,
14, 15]. Interestingly, a recent study has shown that
GLRA1 subunits with a recessive mutation p.E375X trun-
cating upstream of TM4 domain are incorporated into
functional pentametric GLRs and retain glycine sensitivity
[43]. We propose the human GLRA4 protein lacking TM4
is not a pseudogene, but is required for the assembly and
stability of some heteromeric GLRs. This is also substanti-
ated by high levels of GLRA4 transcripts detected in vari-
ous part of the human brain including the cerebellum and
hippocampus. Furthermore, we cannot exclude the possi-
bility that GLRA4 transcripts may also play a regulatory
role in the brain by modulating transcription of other
GLR genes through RNAi due to its high sequence hom-
ology with GLRA1, GLRA2 and GLRA3.
Pseudogenes have previously been shown to have regula-
tory functions [20–22] and may play a role in health and
disease [19, 21]. For instance, pseudogenes of cancer-
related genes have previously been shown to have regula-
tory roles in tumor biology [21] and type 2 diabetes [22] by
modulating the levels of their corresponding functional
gene through posttranscriptional silencing. Our hypotheses
are also in agreement with a study on the γ-aminobutyric
acid type A (GABAA) where alternative splice variants of
the GABAA α4 (including one variant that lacks exon 9
which encodes the TM4 domain), are thought to have a
posttranslational regulatory role [11, 54]. GABAA receptors
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are also chloride-gated ion channel receptors playing
important roles as inhibitory neurotransmitter receptors in
the brain [11, 54, 55].
Conclusion
The clinical features displayed by DGDP084 are consistent
with a neurological dysfunction arising as a result of the
Xq22.2 microdeletion. Our comparative deletion mapping
and RT-qPCR results support the hypothesis that GLRA4
is a novel candidate gene for XLID and is likely involved
in the intellectual disability, behavioral problems, and cra-
niofacial anomalies seen in DGDP084. Additional point
mutations or intragenic deletions of GLRA4 are required
to further substantiate our hypothesis.
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